Also trades as: 0J2O.L (LSE) · $vol 0M
HALO NASDAQ
Halozyme Therapeutics, Inc.
1W: +4.5%
1M: +12.4%
3M: +53.4%
YTD: +82.1%
1Y: +91.4%
3Y: +257.6%
5Y: +244.9%
$128.50
+0.49 (+0.38%)
After Hours: $128.53 (+0.03, +0.02%)
Weekly Expected Move ±4.8%
$114
$120
$126
$132
$138
Credit Risk of going bust: lower than 70% of companies Debt: 12.9% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Cash Flow Trends
Operating Cash Flow
$652M
+36.0% ▲
5Y CAGR: +63.7%
Capital Expenditures
$7M
+34.8% ▲
5Y CAGR: +22.7%
Free Cash Flow
$645M
+37.6% ▲
5Y CAGR: +64.8%
Dividends Paid
$0
+0.0% ▲
Buybacks
$342M
-36.9% ▼
Net Change in Cash
$21M
+916.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $403M | $202M | $282M | $444M | $317M |
| Depreciation & Amort. | $7M | $57M | $85M | $89M | $88M |
| Stock-Based Comp. | $21M | $24M | $37M | $43M | $52M |
| Change in Working Capital | $3M | -$110M | -$39M | -$136M | -$152M |
| Other Non-Cash Items | -$133M | $67M | -$10M | $39M | $347M |
| Operating Cash Flow | $299M | $240M | $389M | $479M | $652M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1M | -$5M | -$15M | -$11M | -$7M |
| Acquisitions (Net) | $0 | -$999M | $0 | $0 | -$726M |
| Investment Purchases | $0 | $0 | -$293M | $0 | -$247M |
| Investment Sales | $0 | $0 | $211M | $0 | $722M |
| Other Investing | -$405M | $517M | $0 | -$252M | -$288M |
| Investing Cash Flow | -$406M | -$487M | -$97M | -$263M | -$546M |
| — Financing Activities — | |||||
| Net Debt Issuance | $416M | $625M | -$13M | $0 | $235M |
| Stock Repurchased | -$350M | -$200M | -$402M | -$250M | -$342M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $12M | -$62M | $8M | $31M | $0 |
| Financing Cash Flow | $78M | $362M | -$408M | -$219M | -$85M |
| Net Change in Cash | -$29M | $115M | -$116M | -$3M | $21M |
| Cash End of Period | $119M | $235M | $118M | $116M | $136M |
| Free Cash Flow | $298M | $235M | $373M | $468M | $645M |